Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 10/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20258696 | 0.90 | PPARD (0.40) | PPARDPPARATLR7NPC1GALR3 | |
| SCHEMBL16756248 | 0.85 | PPARD (0.40) | PPARDPPARATLR7NPC1GALR3 | |
| SCHEMBL16756585 | 0.85 | TLR7 (0.40) | PPARDPPARATLR7NPC1GALR3 | |
| SCHEMBL16756485 | 0.83 | PPARD (0.43) | PPARDPPARATLR7 | |
| SCHEMBL16756311 | 0.82 | TNF (0.46) | TLR7TNF | |
| SCHEMBL15559117 | 0.82 | PPARD (0.37) | PPARDPPARATLR7NPC1GALR3 | |
| SCHEMBL16756301 | 0.82 | TLR7 (0.38) | PPARDPPARATLR7NPC1GALR3 | |
| SCHEMBL16756380 | 0.81 | GALR3 (0.39) | PPARDPPARATLR7NPC1GALR3 | |
| SCHEMBL16756280 | 0.80 | TLR7 (0.38) | PPARDPPARATLR7NPC1GALR3 | |
| SCHEMBL16756480 | 0.80 | TLR7 (0.37) | PPARDPPARATLR7TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550737-B2 | TNF -α modulating benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2017-01-24 | — | — | US | disclosed |
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | TNF, TNFRSF1A, NFKBIA | PPARD 537/4885PPARA 1431/4885TLR7 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.